Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Autor: M B Manning, D A Streja, C Keller, C H Chung, P L Beckett, A Özdemir, Y M Cho, I Colin, L J Aronne, Erik Christiansen, Markus Laimer, L Van Gaal, S N Lederman, T M O'Connor, L J Klaff, S Aronoff, S H Baik, A V Murray, Signe O R Wallenstein, N A Godbole, H O Høivik, Dilek Gogas Yavuz, A Golay, G T'Sjoen, B Delgado, I N El Ebrashy, E S Kang, C Wium, Bruce W. Bode, Ramazan Sari, B A Palchick, J Geohas, P R Nicol, M Winnie, N Aladağ, E W Braun, C Vercammen, S A Shelbaya, K Sivalingam, S Gorban de Lapertosa, E Riffer, F G Eliaschewitz, J B Buse, B Schultes, C H Sorli, K-W Lee, Mark Warren, T Pieber, S Stäuble, R Prager, A Mertens, A A Arif, D C Eagerton, A Scheen, I J Kim, J A Seo, S Ong, E Ataoglu, John B. Buse, D Berker, A White, F Helland, J C LaRocque, Young Min Cho, Christin L. Hertz, E M Palace, L H S Canani, M P Finneran, S H A Khalil, H L Gulseth, D Weiss, J Condit, E Fließer-Görzer, L Rista, S Akın, M H M F El Hefnawy, N H Kim, C Issa, S Bilz, H Bays, S Fischli, V Preumont, J Pereles-Ortiz, B Bode, E J Morawski, Aytekin Oguz, J Cooper, Tamer Tetiker, Ann Mertens, G Rudofsky, Thomas R. Pieber, W R Litchfield, J L Gross, D L Weinstein

Publikováno v: The lancet. Diabetesendocrinology. 7(7)

BACKGROUND: Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the efficacy and safety of flexible dose adjustments of oral semaglut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e132376f3cbf48c52376523aef27e59f
https://pubmed.ncbi.nlm.nih.gov/31320282

Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variation

Autor: J. B. Buse, K. Yasuda, T. P. Lay, T. S. Seo, A. L. Olson, J. E. Pessin, J. H. Karam, S. Seino, G. I. Bell

Publikováno v: Diabetes. 41:1436-1445

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::519ccf8c32ab614b4173691b3db7d2bd
https://doi.org/10.2337/diabetes.41.11.1436

Panel discussion on achieving glycemic control

Autor: J B, Buse, D, Einhorn

Publikováno v: Postgraduate medicine. 110

This discussion contains excerpts from the satellite symposium, "Achieving Better Glycemic Control Through Management of Mealtime Glucose," presented at the American Association of Clinical Endocrinologists Tenth Annual Meeting and Clinical Congress

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d7b1a6b06001884c623602f0083aae23
https://pubmed.ncbi.nlm.nih.gov/19667581

Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy

Autor: J B, Buse

Publikováno v: Diabetes care. 22

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6b8c4b01e9f66d4852ecdf71813e9627
https://pubmed.ncbi.nlm.nih.gov/10189565

Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group

Autor: J B, Buse, B, Gumbiner, N P, Mathias, D M, Nelson, B W, Faja, R W, Whitcomb

Publikováno v: Diabetes care. 21(9)

To determine the ability of troglitazone to reduce requirements for injected insulin while maintaining blood glucose levels in insulin-treated patients with type 2 diabetes.This 26-week double-blind study with open-label extension included patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::997da5d4f7ffaa1c509a4fb2dd18dba9
https://pubmed.ncbi.nlm.nih.gov/9727881